Pharmaceuticals

FDA grants accelerated approval to Novartis’ Favarta for primary IgA nephropathy

bexib
By bexib 0 Min Read

The accelerated approval of Fabhalta for the treatment of primary IgA nephropathy is based on positive results from the Phase 3 APPLAUSE-IgAN trial.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article What does Bitcoin mean to you? An interview with Marco Santini
Next Article Stellar shines with 11% gain despite market drop – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Technology for designing multipurpose sleeping spaces
Hospitality & Tourism
Calculated Risk: COVID Update September 13: Wastewater Measures Remain High
Economy
Lipow’s examination of the relationship between homeownership and unemployment
Economy
Second regional housing market survey in August
Economy